Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin

SIMPLE SUMMARY: Gemtuzumab Ozogamicin (GO) is a drug approved for the treatment of acute myeloid leukemia (AML). It targets leukemic cells that express the CD33 molecule on their surface and brings the toxic agent calicheamicin inside the cell to kill it. Several studies have shown that AML patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Gottardi, Michele, Simonetti, Giorgia, Sperotto, Alessandra, Nappi, Davide, Ghelli Luserna di Rorà, Andrea, Padella, Antonella, Norata, Marianna, Giannini, Maria Benedetta, Musuraca, Gerardo, Lanza, Francesco, Cerchione, Claudio, Martinelli, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469571/
https://www.ncbi.nlm.nih.gov/pubmed/34572794
http://dx.doi.org/10.3390/cancers13184566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469571/
https://www.ncbi.nlm.nih.gov/pubmed/34572794
http://dx.doi.org/10.3390/cancers13184566

Ejemplares similares